Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

A large cohort study examining more than 125,000 adults in the U.S. found that the majority of patients discontinue GLP-1 RA therapy within the first year, with those without Type 2 diabetes showing ...

Some of the most common peptides for weight loss belong to a class of drugs called glucagon-like peptide 1 (GLP-1) receptor agonists. These medications mimic the action of the natural hormone GLP ...

As of Jan. 29, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications.

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

This rapid sequence generation process ... benefits and impact of the AI-driven peptide discovery pipeline, the potential for computationally designed GLP-1 analogs to improve therapeutic efficacy ...

UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...

As glucagon-like peptide 1 (GLP-1) receptor agonist use becomes more prevalent, patients are using them for new indications — and at new dosages. Say hello to microdosing, or taking doses lower ...

A new study reports that GLP-1 medications may provide benefits to cognitive and behavioral health, including lowered addiction risk. Scientists also confirmed that the use of these medications ...